Abstract Number: 1667 • ACR Convergence 2022
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…Abstract Number: 1752 • ACR Convergence 2022
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…Abstract Number: 1951 • ACR Convergence 2022
Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis…Abstract Number: 1967 • ACR Convergence 2022
Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
Background/Purpose: Early work cessation and reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We…Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…Abstract Number: 2179 • ACR Convergence 2022
Spatial and Single-Cell Transcriptomics Identify Alcam+ Macrophage / CD6+ T-Cell Interactions and Accumulation of IgG2b+ Class-Switched Plasma Cells in Marco+ Medullary Sinuses of Joint-Draining Popliteal Lymph Nodes in TNF-Tg Mice with Advanced Arthritis
Background/Purpose: Severe inflammatory-erosive arthritis in tumor necrosis factor transgenic (TNF-Tg) mice is associated with B-cell translocation into sinuses of joint-draining popliteal lymph nodes (PLNs) via…Abstract Number: 2234 • ACR Convergence 2022
Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Background/Purpose: Obesity has been linked to chronic pain and pain sensitization in the general population and among patients with rheumatoid arthritis (RA). The mechanism by…Abstract Number: 0050 • ACR Convergence 2022
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid…Abstract Number: 0095 • ACR Convergence 2022
Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
Background/Purpose: While a treat-to-target strategy is endorsed by the ACR RA Treatment Guidelines, many patient, social, and healthcare system factors make implementation of this approach…Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…Abstract Number: 0270 • ACR Convergence 2022
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Background/Purpose: Anti-SARS-CoV2 mRNA vaccination may result in blunted humoral immune responses with lower peak titers and a different kinetic in patients with rheumatic diseases receiving…Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 188
- Next Page »